Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Cediranib (Primary) ; Lenalidomide (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 30 Sep 2018.
- 10 Jun 2017 Biomarkers information updated
- 20 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2017.